Page 14 - Pharma Stocks

Aurobindo Pharma's new injectable facility get 10 observations from US FDA

"The observations are procedural and will be responded to within the stipulated time," the company stated in a regulatory filing

Nifty Metal eyes consolidation, Nifty Pharma trades with negative bias

The advised strategy for the Nifty Metal index is to buy near support levels and sell near resistance

Laurus Labs slips 4% as arm gets 5 observations post USFDA inspection

Laurus Synthesis Private Limited has been issued a Form 483 with five observations and the company plans to address the observations within stipulated timelines.

Lupin Ltd receives USFDA approval for smoking cessation drug Chantix

The product will be manufactured at Lupin's Pithampur facility in India, the company said in a regulatory filing

Aurobindo Pharma hits 52-week high, jumps nearly 4% in a weak market

The stock has been one of the top out-performers so far this month, and gained a whopping 18.5 per cent.

Biocon jumps 4% on the back of strong Q2 performance

The stock had shed 16 per cent in Samvat 2079. So far in 2023, the stock has declined 9 per cent as against a near 7 per cent gain on the BSE benchmark.

Cipla Q2 net profit seen rising 25% YoY; US sales may drop QoQ to $215 mn

Cipla Q2FY24 result preview: On a sequential basis (QoQ), Cipla's net profit is seen declining 1.1 per cent, while revenue may grow 2.2 per cent

Biocon slips 4% after USFDA asks for corrective measures at Malaysian unit

The USFDA has determined the inspection classification as 'OAI' (Official Action Indicated) post inspection of Biocon's step-down subsidiary in Malaysia.

Glenmark Pharma soars 10% after S&P Global upgrades outlook to positive

The rating agency expects Glenmark to significantly reduce debt on completion of the GLS sale and maintain healthy earnings.

Bajaj Healthcare zooms 53% in four weeks on healthy FY24 guidance

EBITDA margins would be in the range of 16 -20 per cent for the FY24, mainly driven by growth in the formulation biz and with the introduction of reverse engineering APIs launched in the last fiscal.

Lupin hits 2-year high on strong Q1 results; zooms 66% since April

With clearance of Pithampur Unit-2, the company expects to add product approvals for the US region

Cipla hits new high; up 6% on promoter stake sale buzz, strong Q1 results

With regards to the promoters stake sale buzz, the company said it will make appropriate disclosure in compliance with the Listing Regulations as and when any such requirement arises.

Sun Pharma Q1 profit may be weighed by weak US generic sales and Taro nos

Sun Pharma Q1 results: The company's Q1 net profit could dip fractionally by 0.15 per cent to Rs 2,058 crore against Rs 2,061 crore reported a year ago

Ajanta Pharma rallies 9%; hits record high on strong Q1 results

In past one week, the stock has surged 19 per cent and rallied nearly 40 per cent so far this calendar year.

Cipla surges 9% on strong Q1 results, raises FY24 margin guidance

For FY24, Cipla raised its EBITDA margin guidance to 23 per cent from 22 per cent earlier.

Cipla Q1 preview: India biz may push profit over 50% QoQ; US sales to drag

Cipla Q1 preview: The company's domestic business can grow 15 per cent quarter-on-quarter (QoQ), while US business could contract by up to 4 per cent QoQ to $195 million

Dr Reddy's gains nearly 3% post completion of USFDA inspection at AP unit

The stock hit a fresh 52-week high at Rs 5,360, and has rallied over 19 per cent in less than two months.

Pharma stocks rally on lower price erosion, hopes of US generic mkt uptick

Pharma players with a major exposure to US mkt such as Sun Pharma, Lupin, Zydus Life, Dr Reddy's, Aurobindo, Torrent have been outperformers hitting their 52-week highs over the last couple of weeks

Spiriva approval gives earnings visibility to Lupin; valuations expensive

Lupin's shares declined 4.5 per cent in Thursday's intra-day trade

Ajanta Pharma hits 52-week high on upbeat branded generic business outlook

The management is confident to scale up margins again in the coming years on the back of enhanced contribution from Branded Generics business and normalisation of freight costs